Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

Pancreas development in pigs resembles humans much more closely than does the established mouse model. An international team ...

Arabidopsis thaliana was always an unlikely candidate for the limelight. But 25 years ago, the diminutive thale cress ...

Thank you, operator. Good morning and good afternoon, everybody, and thank you for joining BioNTech's Third Quarter 2025 Earnings Call. As a reminder, the slides we'll use during the call and the ...

Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Precision targeting in MPN Session Date and Time: December 6, 2025; 9:30 AM – 11:00 AM ...

New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of ...

A Northwestern Medicine-led study has identified mutations in the gene CEP76 as a new cause of ciliopathies, shedding light on a complex group of disorders that affect multiple body systems, according ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Q25 – – $32.0 million Revuforj® (revumenib) net revenue; total Revuforj prescriptions in 3Q25 increased 25% over 2Q25, highlighting strong demand – – $45.8 million Niktimvo™ (axatilimab-csfr) net ...